Market Overview

UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on CVS Caremark Corporation

Share:
Related CVS
Canaccord Reiterates On Alere, Boosts Price Target To $60
Benzinga's M&A Chatter for Thursday May 21, 2015
Mizuho Makes Great Case For Rite Aid And Express Scripts Tie-Up (Seeking Alpha)

In a report published Friday, Cantor Fitzgerald reiterated its Buy rating on CVS Caremark Corporation (NYSE: CVS), and raised its price target from $55.00 to $57.00.

Cantor Fitzgerald noted, “Despite some concerns over what CVS could possibly do for an encore following some exceptional tailwinds in 2012, the combination of a major dividend increase and very strong (above consensus) EPS guidance set the tone for a very upbeat analyst meeting. We liked what we heard in the management presentations and have greater conviction in our 2013 earnings outlook. We reiterate our BUY rating with a revised price target is $57 (from $55).”

CVS Caremark Corporation closed on Thursday at $48.50.

Latest Ratings for CVS

DateFirmActionFromTo
Apr 2015JefferiesMaintainsBuy
Feb 2015CitigroupMaintainsNeutral
Feb 2015Deutsche BankMaintainsHold

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...